MTACW (MedTech Acquisition) Notes Receivable: $0.00 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTACW MedTech Acquisition Corp MTACW
22 GF Score
Price $0.22
! 2 Warning Signs
View Full Analysis

What is MedTech Acquisition Notes Receivable?

MedTech Acquisition MTACW +21.11% 22 Notes Receivable is $0.00 Mil as of Jun. 2023. GuruFocus rates MTACW with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

MedTech Acquisition's Notes Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

MedTech Acquisition Notes Receivable Related Terms

MedTech Acquisition Notes Receivable Historical Data

* Premium members only.

The historical data trend for MedTech Acquisition's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedTech Acquisition Notes Receivable Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Notes Receivable
0.00 0.00 0.00

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MTACW
22GF Score
MedTech Acquisition Corp MTACW
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedTech Acquisition Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
MedTech Acquisition (MTACW) has a Notes Receivable of $0.00 Mil as of Jun. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MedTech Acquisition and its competitors.
Is MedTech Acquisition's Notes Receivable too high?
MedTech Acquisition's current Notes Receivable is $0.00 Mil. Overall, MedTech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does MedTech Acquisition's Notes Receivable compare to MON and HCII?
MedTech Acquisition's Notes Receivable of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Diversified Financial Services company?
A good Notes Receivable depends on the Diversified Financial Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MedTech Acquisition and its competitors. MedTech Acquisition's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedTech Acquisition stock overvalued right now?
MedTech Acquisition (MTACW) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. MedTech Acquisition's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For MedTech Acquisition (MTACW), the current Notes Receivable is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedTech Acquisition Business Description

Address 48 Maple Avenue, Greenwich, CT, USA, 06830
MedTech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for MTACW

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price